This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Indiana University, University of Toronto, Uti Limited Partnership. Active years: 2017-2019.
Company Filing History:
2 out of 805 
2 out of 529 
2 out of 139 
Years Active: 2017-2019
Title: Innovations of Sina Haftchenary
Introduction
Sina Haftchenary is an accomplished inventor based in Thornhill, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for cancer treatment. With a total of two patents to his name, Haftchenary's work is recognized for its potential impact on medical science.
Latest Patents
Haftchenary's latest patents focus on salicylic acid derivatives and their pharmaceutically acceptable salts. These inventions relate to novel compounds and compositions designed to inhibit STAT3 and/or STAT5 activity. The methods outlined in his patents aim to provide new avenues for the treatment of STAT3 or STAT5-dependent cancers, showcasing his innovative approach to addressing critical health challenges.
Career Highlights
Throughout his career, Haftchenary has worked with notable institutions, including the University of Toronto and Uti Limited Partnership. His experience in these organizations has allowed him to refine his research skills and contribute to groundbreaking advancements in pharmaceutical science.
Collaborations
Some of Haftchenary's notable coworkers include Patrick Thomas Gunning and Brent David George Page. Their collaborative efforts have likely enriched the research environment and fostered innovative ideas in their respective fields.
Conclusion
Sina Haftchenary's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in cancer treatment and pharmaceutical research.